We have demonstrated the success of this strategy initially with PMBOP-CP NPs40 and now with the new biodegradable PCL-CP NPs (Fig. 4a): the injected NPs were largely concentrated at tumor site along with decreased uptake by liver. The gene discussed is CP; the disease is neoplasm.